Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib in metastatic colorectal cancer after second-line therapy
NCT03403452Phase 2Unknown
- Sponsor
- Fudan University
- Start
- Jan 2018
- Primary completion
- Jun 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of Rivoceranib in metastatic colorectal cancer (mCRC), sponsored by Fudan University. Status: unknown.
02
Drugs
Rivoceranib
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT03403452.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03403452.